In New Zealand, Maori and Pacific children have historically suffered high hospitalization rates for invasive pneumococcal disease (IPD), all cause pneumonia (ACP), and otitis media. Following the introduction of conjugate vaccines in the country, Maori and Pacific children’s rates of admission for IPD dropped by 79% and 67%, respectively, while significant reductions in ACP and otitis media admissions were also noted, resulting in reductions in disparities for these populations.
Pneumococcal disease/PCV/PPSV
Immunization helps protect low-income populations from financial burden and prevents diseases like measles and pneumonia
In a financial risk model analysis of 41 Gavi-eligible countries, the burden of Catastrophic Health Costs (CHC) and Medical Impoverishment (MI) would be greatest in the lowest income populations. With expanded vaccine coverage, the share of prevented cases of measles, pneumococcal disease, and rotavirus, in relation to the total number of cases prevented, would be larger in the lowest income populations thereby providing a larger financial risk protection (FRP) to these populations.
Vaccine coverage in Gavi-eligible countries associated with significant reductions in catastrophic health costs
In 41 Gavi-eligible countries, in the absence of vaccine coverage, the number of Catastrophic Health Costs (CHC) cases caused by measles would be 18.9 million, by severe pneumococcal disease would be 6.6 million and by severe rotavirus disease would be 2.2 million. Expanding vaccine coverage in these countries would reduce the number of cases of CHC due to measles by 90%, due to pneumococcal disease by 30% and due to rotavirus disease by 40%.
Vaccination can help prevent impoverishment, especially in low-income populations
In a study modeling the economic impact of immunization in 41 low- and middle-income countries, the authors estimate that 24 million cases of medical impoverishment would be averted through the use of vaccines administered from 2016-2030. The largest proportion of poverty cases averted would occur in the poorest 40% of these populations, demonstrating that vaccination can provide financial risk protection to the most economically vulnerable.
Vaccination can prevent over a million cases of poverty in low- and middle-income countries
Vaccines that can protect against pneumonia – Hib and S. pneumoniae vaccines – can together prevent over 1.25 million cases of poverty over 15 years, found researchers modeling the economic impact of immunization in 41 low- and middle-income countries.
Immunization can prevent medical debts and improverishment, particularly in the poorest populations
A study modeling the economic impact of 10 childhood immunizations in 41 low- and middle-income countries found that the bulk of poverty averted through vaccination occurs in poor populations. For most of the vaccines in the study, at least 40% of the poverty averted would occur in the poorest wealth quintile. Particularly for pneumonia, more than half of the two million deaths averted by pneumococcal and Hib vaccines would occur in the poorest 40% of the population.
Vaccination provides additional protection for children who are HIV positive, protecting them from preventable infections
A review of evidence for the use of pneumococcal conjugate vaccine in South Africa showed that children who are HIV positive are at significantly increased risk of pneumococcal disease, and so will benefit the most from vaccination, despite decreased vaccine efficacy in this group compared to healthy children.
The pneumococcal conjugate vaccine was associated with a decline in antibiotic-resistant pneumococcal cases in South Africa
This study from South Africa demonstrates significant declines in invasive pneumococcal disease cases caused by bacteria that are resistant to one or more antibiotics. In fact, the rate of infections resistant to two different antibiotics declined nearly twice as much as infections that could be treated with antibiotics.
Treatment of vaccine-preventable pneumococcal disease carries a heavy financial toll for health systems and families
In a study in The Gambia – a setting where healthcare is free of charge to patients – pneumococcal disease nonetheless placed a heavy financial burden on families seeking treatment before arrival at the hospital, with families paying for transportation costs, drugs, diagnostic tests and even burial in the case of death. 50-80% of the cost of treating an episode of pneumococcal disease was born by the health system, which still left families to cover a cost up to 10 times their average daily household budget. In addition the estimated treatment cost for inpatient pneumonia of US$109 is nearly 4 times the annual per capita expenditure for health in The Gambia.
Pneumococcal disease can impair cognitive development
A study analyzing the long-term consequences of middle ear disease in children in an urban health center and a private practice in the United States found that time spent with middle ear effusion during the first 3 years of life was significantly associated with lower school performance and lower scores in cognitive ability, speech, and language.